Host Pharmacogenomic Variation in AL-Treated Malaria
This project contains targeted amplicon sequencing data generated to investigate host pharmacogenomic variation and its potential relationship with parasite clearance following artemether-lumefantrine (AL) treatment in patients with uncomplicated Plasmodium falciparum malaria in Lagos, Nigeria. Archived dried blood spot (DBS) samples from participants enrolled in a previous 28-day AL therapeutic efficacy study were used for host DNA analysis. Targeted sequencing was performed across selected pharmacogenes, including CYP450 and NAT2 loci, to characterise genetic variation potentially relevant to antimalarial drug metabolism and treatment response. The resulting sequence data support investigation of host genetic diversity and its relationship with parasite-clearance kinetics and treatment outcomes following AL therapy.